RT @ericdeinmd: Conaghan: "Most promising study in OA" at #RNL2023 NGF inhibitor to OA had benefit, but very poorly tole
Tweet Content
Conaghan: "Most promising study in OA" at #RNL2023
NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated?
Can there be sustained response.
Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪
@RheumNow https://t.co/eBMEPBG9wn
Show on Archive Page
On
Display in Search Results
On
PDQ
Off